

EARLY DISCOVERY OF NEW ANTIBIOTICS WORKSHOP
12-13 January
Auditorium
Bio Park, 11 rue Watt, 75013 Paris, France

AGENDA

Workshop Aim:

- Share ideas on antibiotic development between upstream and developers by bringing the PIs in projects areas of AB early discovery and those in clinical development in order to identify potential candidates and increase awareness of entry requirements
- Increase awareness at early stage of entry requirements about future clinical development
- Showcase early work on screening and identification of new targets
- Exchange experiences, approaches and lessons learnt
- Alignment of programmes

DAY ONE: 12 January 2017

13:30 – 14:00 Registration

14h INTRODUCTION AND WELCOME

14:00 – 14:10 Welcoming words from the organizing committee

By Carlos Segovia, JPIAMR Chair

By Antoine Andremont, University Paris-Diderot Medical School, France

14:10 SESSION 1: Target oriented Antibiotic discovery

Moderator: *Antoine Andremont, University Paris-Diderot Medical School, France*

Rapporteur: *Barbara Junker, DLR, Germany*

Introduction: challenges to bring a new antibiotic to the market

14:15 – 14:45 IMI-ENABLE: A European Antibacterial Drug Discovery Platform

By Eric Bacqué, Sanofi

- 14:45 – 15:05 NABARSI (drug development)
By Aigars Jirgensons, Latvian Institute for Organic Synthesis
- 15:05 – 15:25 NAPCLI Non-conventional approaches for peptidoglycan cross-linking inhibition
By Michel Arthur, INSERM, University Pierre et Marie Curie; University Paris Descartes, Paris, France.
- 15:25 – 15:45 NoTBsec New intervention strategy for tuberculosis: blocking multiple essential targets
By Magnus Steigedal, Norwegian University of Science and Technology
- 15:45 – 16:10 Questions
- 16h10 – 16h30 *Break*
- 16:30 – 16:50 NPERDMDR Investigating the Mechanism of Eradication of Multi Drug Resistant Bacteria by Inorganic (mixed metal oxides), Organic (antibiotic), and Protein-based Nanoparticles
By Aharon Gedanken, Bar-Ilan University, Israel
- 16:50 – 17:10 SenBioTAR Sensing *Pseudomonas aeruginosa* biofilms to antibiotic and reducing virulence through novel target inhibition.
By Miguel Camara, University of Nottingham, United Kingdom
- 17:10 – 17:30 DesInMBL: Structure-guided design of pan inhibitors of metallo- β -lactamases.
By Thierry Naas, University of Paris Sud, Paris, France
- 17:30- 18:00 Questions
- 18h00 *End*
- 19:00 **Working dinner**

DAY TWO: 13 January 2017

8:45 – 9:00 *Registration*

SESSION 2: Discovery of new Antibiotics

Moderator: *Jonathan Pearce, MRC, UK*

Rapporteur: *Antoine Andremont, University Paris-Diderot Medical School, France*

9:00 – 9:30 Introduction to ND4BB Presentation Translocation
*By Mathias WINTERHALTER, Department of Life Sciences & Chemistry
Jacobs University Bremen, Germany*

9:30 – 9:50 FORMAMP (nanotech/antimicrobial peptides)
By Helena BYSELL, SP Technical Research Institute of Sweden

9:50 – 10:10 AIDA (combination therapy)
*By Johan MOUTON, Erasmus University Medical Center / Dept. of Medical
Microbiology and Infectious Diseases [EMC], Netherlands.*

10:10 – 10:30 REBeL Repotentiating Beta Lactam antibiotics
*By Mariel Pikkemaat, RIKILT, Institute of Food Safety Wageningen,
University and Research Centre, Netherlands.*

10:30 – 10:50 Questions

10:50 – 11:00 *Break*

11:00 – 11:20 EVOBIOTIC Capturing the natural antibiotic'ome: Developing Nature's
EVOLved AntiBIOTIC Collective
By Jean-Luc Pernodet, University Paris Sud

11:20 – 11:40 ABIMMUNE Repurposing disused antibiotics with immune modulators as
antimicrobial strategy for respiratory tract infections
*By Jean-Claude SIRARD, Institut Pasteur de Lille, Centre d'Infection et
d'Immunité, Lille, France*

11:40 – 12:00 CO-ACTION Developing combinations of CO-ACTIVE antimicrobials and non-antimicrobials
By Johan MOUTON, Erasmus University Medical Center / Dept. of Medical Microbiology and Infectious Diseases [EMC], Netherlands

12:00 – 12:30 Questions

12:30 – 13:30 *Lunch*

13:30 – 13:50 COMBINATORIALS Novel drugs and drug combinations against bacterial growth, survival and persistence from high-throughput screening to mechanism of action
By Athanasios TYPAS, European Molecular Biology Laboratory, Genome Biology Unit, Germany.

13:50 – 14:20

JPIAMR WGs/Networks (‘05 min each):

- *Jerry Wells - Wageningen University – Histidine Kinase Inhibitors as Novel Anti-infective*
- *Klaas Pos - Goethe University Frankfurt – Exploiting an old drug for inhibitory discovery*
- *Laurent Debarbieux - Institut Pasteur – PhageForward project*
- *Pierre-Alain Bandinelli - Da Volterra – BEAM Alliance*

14:20 – 14:40 Questions

14:40 – 15:30

SESSION 3: WAY FORWARD AND CLOSING REMARKS

Moderator: *Laura Piddock, Birmingham University, UK*

- Round table: Analysis of the current European level portfolio: how to synergize the approaches, how to progress for new strategies / optimize funding around discovery
- Alignment of programmes
- Closing remarks

15:30 Meeting Ends